Cross-Sector entity
That works out to roughly 1.4 stories per week across a 25-day span. The busiest single day carried 2. The clearest coverage concentration is pharma: 3 of 5 stories, with the rest divided among 2 other categories. Boston Scientific is most often covered alongside Biote, which appears in 2 of these 5 stories.
5 verified stories tracked
Last mentioned: Mar 23, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 20 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
That works out to roughly 1.4 stories per week across a 25-day span. The busiest single day carried 2. The clearest coverage concentration is pharma: 3 of 5 stories, with the rest divided among 2 other categories. Boston Scientific is most often covered alongside Biote, which appears in 2 of these 5 stories. We currently track 5 Cross-Sector stories that mention Boston Scientific, published between February 27, 2026 and March 23, 2026. The tracked stories average 5 original sources each. 20% of these stories carry negative sentiment.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Boston Scientific. Shared-story counts are live from our verified record — not editorial picks.
NXT 41X Launch
Anticipated commercial launch of Elutia's next-gen drug-eluting biomaterial.
Lead Plaintiff Deadline
Expected deadline for shareholders to petition the court to serve as lead plaintiff in the case.
Bumble 2.0 Launch
Targeted launch of AI-enabled platform experience.
Secondary Notice
Pomerantz reinforces the filing highlights to ensure broad investor awareness.
Follow-up Disclosure
Secondary announcements highlight the filing and the process for shareholders to join the litigation.
Initial Legal Notice
Pomerantz LLP issues the first public call for shareholders to join the class action.
Class Action Announcement
Pomerantz LLP first alerts investors to the class action filing against Boston Scientific.
Codexis CDMO Expansion
Announced three major CDMO agreements with Bachem, Nitto Avecia, and Axolabs.
SEC 8-K Filing
BSX files a Form 8-K under Item 8.01 (Other Events), potentially triggering market reaction.
Earnings Report
Boston Scientific reports Q4 2025 financial results and provides 2026 guidance.
Elutia FDA Milestone
Expected FDA submission for NXT 41X product line.
Elutia Divestiture
Completed $88M sale of bioenvelope business to Boston Scientific.
Pomerantz LLP has initiated a class action lawsuit against Boston Scientific (BSX), alleging potential violations of federal securities laws. The litigation centers on the company's disclosures during a period of significant expansion and product integration, marking a critical legal challenge for the medical device giant.
Pomerantz LLP has issued a formal notice regarding a class action lawsuit against Boston Scientific Corporation (BSX), alleging potential securities fraud. The litigation focuses on whether the medical technology giant made misleading statements regarding its product pipeline or regulatory compliance during the class period.
Source: pr-inside.com · pr-inside.com
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
The Q4 2025 earnings cycle for mid-cap healthcare and life sciences firms reveals a strategic shift toward high-margin AI integration and portfolio streamlining. Companies like Elutia and Codexis are leveraging divestitures and technology transfers to shore up balance sheets, while AI-driven productivity gains are becoming a primary differentiator in clinical and operational workflows.
The Australian government is significantly reducing subsidies for high-cost spinal cord stimulators following reports of severe patient injuries and a lack of clinical efficacy. This regulatory shift targets a multi-million dollar sector of the medical device market, forcing manufacturers to justify the high price tags of chronic pain technologies.
